Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07624318 | TROP2 NMR Concordance Study | recruiting | — | 3,400 | AstraZenecaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07738172 | Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer(PTR-2) | recruiting | Phase 3 | 154 | National Taiwan University HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07801430 | Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC | recruiting | N/A | 384 | Fudan UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation(LPR-2) | recruiting | Phase 3 | 15 | EuroCityClinic LLCNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809763 | Wireless Wearable Home Prehabilitation for Older Adults With NSCLC | recruiting | N/A | 196 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00001823 | Evaluation for NCI Surgery Branch Clinical Research Protocols | recruiting | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | terminated | Phase 3 | 595 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 8, 2026 | clinicaltrials |
| NCT04092283 | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 660 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT04926662 | Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening Clinics | suspended | — | 320 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05801029 | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations(OSTARA) | active not recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT06195527 | PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC(PEMBRO-K) | recruiting | — | 75 | University Hospital, AngersOTHER_GOV | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06482073 | Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care | recruiting | — | 250 | Mayo ClinicOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06574295 | HTA of NIVATS Based on RWE | completed | — | 876 | Fudan UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06605534 | Leveraging the Emergency Department (LEAD) Study | recruiting | N/A | 100 | Hackensack Meridian HealthOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06862869 | Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy | recruiting | — | 800 | Hoffmann-La RocheINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07130786 | Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases | recruiting | Phase 2 | 150 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07132190 | Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction | recruiting | Phase 2 | 60 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07192991 | Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America(NECTARINE) | recruiting | — | 200 | Latin American Cooperative Oncology GroupOTHER | 4 | Sep 8, 2026 | clinicaltrials |
| NCT07367529 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | recruiting | Phase 1 / Phase 2 | 465 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07554677 | Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study(PReFACe) | recruiting | N/A | 30 | Queen's University, BelfastOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC(BLAZE) | recruiting | Phase 1 / Phase 2 | 62 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806604 | Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer | recruiting | — | 2,572 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806682 | The Effects of Low Intensity Endurance Exercise on Improving Mitochondrial Function, Cell Bioelectrical Impedance Phase Angle, Fatigue and Quality of Life in Lung Cancer Patients With Cancer-related Fatigue | recruiting | N/A | 150 | Taipei Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807696 | Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax(ECTOP-1031) | recruiting | N/A | 1,036 | Fudan UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 29 | Hubei Cancer HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer(RADICAL-IO) | not yet recruiting | Phase 2 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04909164 | The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients(OPTIMUS) | completed | — | 1,519 | Myung-Ju AhnOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05198830 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 41 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT05990946 | Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer | recruiting | N/A | 736 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06400472 | A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | recruiting | Phase 1 | 575 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06641609 | A Phase I Study of CFT8919 in Patients With Advanced NSCLC | recruiting | Phase 1 | 166 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06790355 | ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population | completed | N/A | 2,527 | Shanghai Weihe Medical Laboratory Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 9, 2026source: clinicaltrials